APOGEE THERAPEUTICS INC (APGE) Stock News

NASDAQ:APGE - Nasdaq - US03770N1019 - Common Stock - Currency: USD

35.39 -0.61 (-1.69%)

After market: 35.39 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

APGE Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Yahoo Finance

Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug

24 days ago - By: Yahoo Finance - Mentions: GS EXAS

BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating

a month ago - By: Yahoo Finance - Mentions: MTSR JPM

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

a month ago - By: Yahoo Finance - Mentions: JPM

Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)

a month ago - By: Yahoo Finance - Mentions: PEP

Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors

a month ago - By: Benzinga - Mentions: RUN NDRA HUMA PROK ...

Gold Falls 1%; ProKidney Shares Spike Higher

a month ago - By: Yahoo Finance - Mentions: PEP RGC GFS

GlobalFoundries Stock Pops on AI Chip Designer Acquisition

a month ago - By: Benzinga - Mentions: AGEN LIXT ARTL MBIO ...

12 Health Care Stocks Moving In Monday's Intraday Session

a month ago - By: Investor's Business Daily - Mentions: LLY SNY REGN

Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot

a month ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

a month ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

a month ago - By: Apogee Therapeutics

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

a month ago - By: Apogee Therapeutics

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

2 months ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

3 months ago - By: Zacks Investment Research

Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

3 months ago - By: Apogee Therapeutics

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference